FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation By Ogkologos - October 30, 2025 87 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Shannen Doherty Opens Up About Life After Cancer And BH90210 August 16, 2019 FDA Approves Amivantamab-vmjw for EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung... March 8, 2024 EMA Recommends Refusal of the Marketing Authorisation for Pexidartinib July 3, 2020 How serendipity sent this oncologist in search of a cure for... August 12, 2022 Load more HOT NEWS Addressing the Challenges of Cancer Misinformation on Social Media A Better Biomarker for Cancer Immunotherapy? Germline Pathogenic Variants in CDH1, BRCA2, CHEK2, ATM, and PALB2 Associated... Similarity of Molecular Portraits in Synchronous Bilateral Breast Cancers Could be...
